Crucell and DSM intensify collaboration
DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology company Crucell have expanded their existing PER.C6-based commercial relationship to include new classes of proteins, including biosimilar protein products.
DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology company Crucell have expanded their existing PER.C6-based commercial relationship to include new classes of proteins, including biosimilar protein products.
As part of the agreement, DSM has paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.
The two companies have jointly licensed PER.C6 human cell lines out to third parties as a production platform for monoclonal antibodies and recombinant proteins since 2002.
They recently established the PERCIVIA PER.C6 Development Center in Cambridge, Massachusetts, US, as a joint venture to further develop the cell line and provide a solution for the production of pharmaceutical proteins to licensees utilizing the PER.C6 human cell line in the biotech industry.
The cell line has been developed for the large-scale manufacture of biopharmaceutical products including vaccines. Compared with conventional production technologies, PER.C6 is said to offer excellent safety profile, scalability and productivity under serum-free culture conditions. It also is able to support the growth of both human and animal viruses.
